NCT05602675

A Drug Interaction Study of LY3871801 in Healthy Participants

Evaluation of the Effect of LY3871801 on the Pharmacokinetics of CYP450 Substrates and an OAT1/3 Substrate in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to determine the effect of LY3871801 when administered orally on the levels of methotrexate (part 1), drug cocktail (warfarin, dextromethorphan, and midazolam) and repaglinide (part 2) in the blood stream when administered orally in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 25 days for each participant.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3871801	Administered orally.
DRUG	Methotrexate	Administered orally.
DRUG	Warfarin	Administered orally.
DRUG	Dextromethorphan	Administered orally.
DRUG	Midazolam	Administered orally.
DRUG	Repaglinide	Administered orally.

Timeline

• Start date: 2022-11-02
• Primary completion: 2023-03-29
• Completion: 2023-03-29
• First posted: 2022-11-02
• Last updated: 2023-04-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study